AlagilleD.SoulierJ. P. (1956). Action des enzymes protéolytiques sur le sang total in vitro; modification des facteurs de coagulation et du complement. Sem. Hop. Paris, 32, 355.
2.
AlkjaersigN.FletcherA. P.SherryS. (1959) The mechanism of clot dissolution by plasminJ. clin. Invest., 38, 1086.
3.
AlkjaersigN.FletcherA.P.SherryS. (1962) Pathogenesis of the coagulation defect developing. during pathological plasma proteolytic (“fibrinolytic”) states. II. The significance, mechanism and consequences of defective fibrin polymerisation. J. clin. Invest., 41, 917.
4.
BachmannF.DuckertF.RollerF. (1958). The Stuart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. (Stuttg.), 2, 24.
5.
BellW. N.AltonH. G. (1954). A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature (Lond.), 174, 880.
6.
BiggsR.MacfarlaneR. G. (1962). Human blood coagulation and its disorders.Oxford: Blackwell Scientific Publications.
7.
ClementW. E.McNicolG. P. (1959). The preparation and use of 1311-tagged fibrinogen to demstrate fibrinolysis. J. clin. Path., 12, 544.
8.
DacieJ. V. (1956). Practical haematology.London: Churchill.
9.
DouglasA. S. (1955). The coagulation defect caused by tromexan therapy. Clin. Sci., 14, 601.
10.
DouglasA. S. (1962). Anticoagulant therapy.Oxford: Blackwell Scientific Publications.
11.
DouglasA. S. (1965). Unpublished observations.
12.
DouglasA. S.BiggsR. (1953). The consumption of some components involved in physiological blood coagulation. Glasg. med. J., 34, 329.
13.
FearnleyG. R.BalmforthG.FearnleyE. (1957). Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clin. Sci., 16, 645.
14.
FerreiraH. C.MuratL. G., (1963). An immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states. Brit. J. Haemat., 9, 299.
15.
FletcherA. P.AlkjaersigN.SherryS. (1959). The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J. clin. Invest., 38, 1096.
16.
FletcherA. P.AlkjaersigN.SherryS. (1962a). Fibrinolytic mechanisms and the development of thrombolytic therapy. Amer. J. Med., 33, 738.
17.
FletcherA. P.AlkjaersigN.SherryS. (1962b). Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. clin. Invest., 41, 896.
18.
FletcherA. P.BiedermanO.MooreD.AlkjaersigN.SherryS. (1964). Abnormal plasminogen-plasmin system activity in patients with hepatic cirrhosis: Its cause and consequences. J. clin. Invest., 43, 681.
19.
GlueckH.SherryS.TrollW. (1954). Assay of plasma prothrombin with a synthetic substrate. Proc. Soc. exp. Biol. (N. Y.), 87, 646.
20.
GreenwaltT. J.TriantaphyllopoulosD. C. (1954). Coagulation studies in abruptio placentae complicated by hypofibrinogenaemia. Amer. J. clin. Path., 24, 1246.
21.
HolemansR.GrossR. (1961). Fibrinolytic activities present in human blood platelets. Nature (Lond.189, 238.
22.
HougieC.BarrowE. M.GrahamJ. B. (1957). Stuart clotting defect. I. Segregation of an hereditary haemorrhagic state from the heterogeneous group heretofore called ‘stable factor’ (S.P.C.A., proconvertin, factor VII) deficiency. J. clin. Invest., 36, 485.
23.
IatridisS. G.FergusonJ. H. (1961). Effect of surface and Hageman factor of the endogenous or spontaneous activation of the fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg.), 6, 411.
24.
JohnstonS. A.SchneiderC. L. (1953). The existence of antifibrinolysin activity in platelets. Science, 117, 229.
25.
von KaullaK. N.SwanH. (1958). Clotting deviations in man during cardiac by-pass. Fibrinolysis and circulating anticoagulant. J. thorac. Surg., 36, 519.
26.
KekwickR. A.MackayM. E.NanceM. H.RecordB. R. (1955). The purification of human fibrinogen. J. Biochem., 60, 671.
27.
KlineD. L. (1953). The purification and crystallization of plasminogen (profibrinolysin). J. biol. Chem., 204, 949.
28.
KwaanH. C.McFadzeanA. J. S.CookJ. (1956). Plasma fibrinolytic activity in cirrhosis of the liver. Lancet, 1, 132.
29.
LewisJ. H.HoweA. C.FergusonJ. H. (1949). Thrombin formation. II. Effects of lysin (fibrinolysin, plasmin) on prothrombin, ac-globulin and tissue thromboplastin. J. clin. Invest., 28, 1507.
30.
McNicolG. P.DouglasA. S. (1964). Recent advances in clinical pathology, Series IV., p. 187, London: Churchill.
MelanderB.GlinieckiG.GransrrandB.HanshoffG. (1965). Biochemistry and toxicology of Amikapron (R); the antifibrinolytically active isomer of AMCHA (a comparative study with E-aminocaproic acid). Acta Pharmacol. (Kbh.)22, 340.
33.
MerskeyC.KleinerG.JohnsonA. (1965). Personal communication.
34.
NiewlarowskiS.LattalloZ. (1957). Influence of plasmin on the first coagulation stage. Bull. AcaD' pol. Set. Cl. 2, 5, 219.
35.
NiewiarowskiS.Prou-WartelleO. (1959). Role du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg.)3, 593.
36.
NilssonI. M.OlowB. (1962). Fibrinolysis induced by streptokinase in man. Acta chir. scand., 123, 247.
37.
PlougJ.KjeldgaardN. O. (1957). Urokinase, an activator of plasminogen from human urine 1. Isolation and properties. Biochem. biophys. Acta, 24, 278.
38.
RatnoffO. D.MenzieC. (1951). A new method for the determination of fibrinogen in small samples of plasma. J. Lab. clin. Med., 37, 316.
39.
RemmertL. F.CohenP. P. (1949). Partial purification and properties of a proteolytic enzyme of human serum. J. biol. Chem., 181, 431.
40.
SchneiderC. L. (1959). Etiology of fibrinopenia: Fibrination defibrination. Ann. N.Y. Acad. Sci.75, 634.
41.
SharpA. A. (1964). Pathological fibrinolysis. Brit. med. Bull, 20, 240.
42.
SharpA. A.HowieB.BiggsR.MethuenD. T. (1958). Defibrination syndrome in pregnancy. Value of various diagnostic tests. Lancet, 2, 1309.
43.
SherryS.AlkjaersigN. (1957). Studies on the fibrinolytic enzyme of human plasma. Thrombos. Diathes. haemorrh. (Stuttg.), 1, 264.
44.
SoulierJ. P.MatheyJ.LeBollochA. G.DaumetP.FayetH. (1952). Syndromes hemorrhagiques mortels avec incoagulabilite totale par difibrination et avec fibrinolyse. I. Au cours des exereses pulmonaires. Rev. Haemat., 7, 48.
45.
StefaniniM.MurphyI. S. (1956). Studies on platelets as a source of antifibrinolysin. J. clin. Invest.35, 355.
46.
TagnonH. J.WhirmoreW. F.SchulmanN. R. (1952). Fibrinolysin in metastatic cancer of the prostate. Cancer (Philad.), 5, 9.
47.
TriantaphyllopoulosD. C. (1958). Anticoagulant effect of incubated fibrinogen. Canad. J. Biochem.36, 249.
